Fig. 1.
Fig. 1. Effect of IDV on anti-CD3–induced cell-cycle progression. / (A) PBMCs from control volunteers (n = 5). *, P < .005. (B) PBMCs from HIV-infected children (n = 15). PBMCs from healthy volunteers and HIV-infected children were preincubated without or with different concentrations of IDV for 18 hours followed by activation with anti-CD3 mAb (0.5 μg/mL) for an additional 48 hours, and cells were stained with propidium iodide for cell-cycle profile analysis by multicycle flow cytometry software. In healthy volunteers, cycling cells in S + G2/M phase are represented as percentage (mean ± SD) of total cells for each test condition. For patients, cells in S + G2/M phase in IDV-treated cultures are expressed as a percentage (mean ± SD) of cells in S + G2/M phase in cultures without IDV treatment. *, P < .05.

Effect of IDV on anti-CD3–induced cell-cycle progression.

(A) PBMCs from control volunteers (n = 5). *, P < .005. (B) PBMCs from HIV-infected children (n = 15). PBMCs from healthy volunteers and HIV-infected children were preincubated without or with different concentrations of IDV for 18 hours followed by activation with anti-CD3 mAb (0.5 μg/mL) for an additional 48 hours, and cells were stained with propidium iodide for cell-cycle profile analysis by multicycle flow cytometry software. In healthy volunteers, cycling cells in S + G2/M phase are represented as percentage (mean ± SD) of total cells for each test condition. For patients, cells in S + G2/M phase in IDV-treated cultures are expressed as a percentage (mean ± SD) of cells in S + G2/M phase in cultures without IDV treatment. *, P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal